Can someone please tell me Manish Gupta’s full name?
Thanks in advance
dr.vikas
Excellent results by Jagsonpal Pharma
dr.vikas
2 Likes
Jagsonpal Pharma
Q3 FY 25 concall highlights -
Revenues - 74 vs 47 cr, up 57 pc ( organic growth @ 27 pc )
EBITDA - 17 vs 6 cr ( before ESOP ), up 183 pc. Margins now @ 23 pc vs 12 pc in Dec 23 !!!
PAT - 11 vs 4 cr ( not counting post tax exceptional gain accrued via sale Faridabad facility )
Cash on books @ 132 cr
Company’s 4 focus therapies include -
Gynaecology
Orthopaedics
Pediatrics
Dermatology
Jagsonpal Pharma acquired the operations of Yash Pharma for 92 cr in May 24 and got access to their Derma and Paediatric brands
Aim to launch 4-6 products every year - to sustain organic growth. Aim to keep boosting sales force productivity through various initiatives. Aim to keep clocking 10-12 pc organic growth wef FY 26
Company’s biggest brands include -
Indocap - pain killer used for mensural, dental pains
Maintane Injection - prevents premature labour pain
Metadec - to treat post menopausal osteoporosis
Divatrone - Dydrogestrone ( used to treat infertility )
Lycored - Dietary supplement
Indocap and Divatrone were facing issues wrt counterfeit products being available in the mkt in early part of FY 25. Most of those issues are now behind
Yash Pharma’s business is now clocking margins very close to consol corporate avg. There has been a massive turnaround in the margins of the acquired business
Should reach a cash balance of 150 cr by end of Mar 25. Will be used for inorganic acquisitions ( Pharma brands in India ) - if not possible, then dividends
MR productivity @ 2.6 lakh / month - have a huge headroom for growth. Not likely to increase MR strength in near term
Going fwd - Aim to keep expanding Gross margins by 120-150 bps / yr
Company launched a new branded product - MemUp in Q1. It’s a hormone replacement therapy for management of menopause symptoms. Haven’t achieved much financial success with the product as yet. But its a promising product - going fwd
As the Divatrone sales come back ( after the resolution of counterfeit issues ), it should help company boost its growth rates wef Q4
Company is ranked no 8 in the Gynae mkt in India. Ortho, Pedia, Derma account for 20 pc, 12 pc and 13 pc of company sales. 55 pc of sales come from the Gynae division
Disc: holding, biased, added recently, not SEBI registered, not a buy/sell recommendation
3 Likes